Q1 Surgical Equipment & Consumables - Specialty Earnings Review: First Prize Goes to Intuitive Surgical (NASDAQ:ISRG)

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including Intuitive Surgical (NASDAQ:ISRG) and its peers.

The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly.

The 4 surgical equipment & consumables - specialty stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 2.7% while next quarter’s revenue guidance was 1.1% below.

Luckily, surgical equipment & consumables - specialty stocks have performed well with share prices up 15.8% on average since the latest earnings results.

Best Q1: Intuitive Surgical (NASDAQ:ISRG)

Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties.

Intuitive Surgical reported revenues of $2.77 billion, up 23% year on year. This print exceeded analysts’ expectations by 5.8%. Overall, it was a stunning quarter for the company with a beat of analysts’ EPS estimates.

Intuitive Surgical achieved the biggest analyst estimate beat of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 5.6% since reporting and currently trades at $425.98.

We think Intuitive Surgical is a good business, but is it a buy today? Read our full report here, it’s free.

Integra LifeSciences (NASDAQ:IART)

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Integra LifeSciences reported revenues of $391.9 million, up 2.4% year on year, outperforming analysts’ expectations by 2.6%. The business had a strong quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.

Integra LifeSciences scored the highest full-year guidance raise among its peers. The market seems happy with the results as the stock is up 67.7% since reporting. It currently trades at $17.86.

Is now the time to buy Integra LifeSciences? Access our full analysis of the earnings results here, it’s free.

Teleflex (NYSE:TFX)

With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide.

Teleflex reported revenues of $548.3 million, up 32.3% year on year, exceeding analysts’ expectations by 2.8%. Still, it was a mixed quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates.

Interestingly, the stock is up 8.5% since the results and currently trades at $133.77.

Read our full analysis of Teleflex’s results here.

LeMaitre (NASDAQ:LMAT)

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

LeMaitre reported revenues of $66.55 million, up 11.2% year on year. This number was in line with analysts’ expectations. It was a strong quarter as it also recorded a beat of analysts’ EPS estimates.

LeMaitre pulled off the highest guidance raise but had the weakest performance against analyst estimates and weakest full-year guidance update among its peers. The stock is down 7.4% since reporting and currently trades at $103.74.

Read our full, actionable report on LeMaitre here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand-wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.